Last update Dec. 20, 2021
Very Low Risk
Glucagon-like peptide 1 analogue that stimulates endogenous insulin secretion. Used to treat obesity and type 2 diabetes in combination with other oral antidiabetics, especially metformin. Administered subcutaneously. The most common side effects are nausea, vomiting and diarrhea. Low risk of hypoglycemia in monotherapy.
Since the last update we have not found published data on its excretion in breast milk.
Its pharmacokinetic data (high molecular weight and high percentage of plasma protein binding) make it very unlikely that significant amounts will pass into breast milk. (Serrano 2014)
Due to its protein nature, it deteriorates in the gastrointestinal tract, not being absorbed (Serrano 2014). This low oral bioavailability would make it difficult for it to pass to the infant’s plasma ingesting breast milk, except in preterm infants and in the immediate neonatal period when there may be increased intestinal permeability.
Diet, exercise, and breastfeeding improve blood sugar levels.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM